LUCD 0.85 Lucid Diagnostics Inc.
| Range: | 0.63-1.58 | Vol Avg: | 186317 | Last Div: | 0 | Changes: | 0 |
| Beta: | 1.47 | Cap: | 0.05B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Oct 14 2021 | Empoloyees: | 70 | ||
| CUSIP: | 54948X109 | CIK: | 0001799011 | ISIN: | US54948X1090 | Country: | US |
| CEO: | Dr. Lishan Aklog M.D. | Website: | https://www.luciddx.com | ||||
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow